Atopic Dermatitis / Atopic Eczema – Unmet Need – Unmet Need – Moderate to Severe Topical-Refractory Atopic Dermatitis (US/EU)

Topical therapies such as corticosteroids and calcineurin inhibitors are the mainstay of treatment of atopic dermatitis; however, for patients with moderate to severe disease, topical options are often insufficient, necessitating systemic treatment. Systemic therapies such as immunosuppressants and corticosteroids remain central to the treatment of this population, but the approval of dupilumab (Sanofi / Regeneron’s Dupixent) and the subsequent approvals of other targeted treatments for this patient cohort (e.g., abrocitinib [Pfizer’s Cibinqo]; tralokinumab [LEO Pharma’s Adbry / Adtralza]; upadacitinib [AbbVie’s Rinvoq]) have expanded the armamentarium of systemic options. Yet these agents are not without drawbacks (e.g., safety risks, inconvenient delivery). This analysis explores the unmet needs in the treatment of moderate to severe topical-refractory atopic dermatitis and the opportunities that exist for new therapies targeting this patient population.

Questions answered

• What are surveyed dermatologists’ opinions of the performances of key current therapies (e.g., abrocitinib, dupilumab, tralokinumab, upadacitinib) on key clinical attributes?
• What are the top areas of unmet need and opportunity in the treatment of moderate to severe topical-refractory atopic dermatitis?
• Based on the responses of surveyed physicians, what is the level of unmet need among key clinical attributes?
• Based on a conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and price are acceptable to dermatologists for a hypothetical new drug treating moderate to severe topical-refractory atopic dermatitis?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 37 European dermatologists fielded in January 2025

Key drugs: Abrocitinib, (Cibinqo), dupilumab (Dupixent), cyclosporine, methotrexate, prednisone, tralokinumab (Adbry / Adtralza), upadacitinib (Rinvoq)

Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

Product description

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.